ArticleNeoplasia (New York, N.Y.)2015

Targeting the pro-survival protein MET with tivantinib (ARQ 197) inhibits growth of multiple myeloma cells.

Shadia Zaman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.